Conversion From Brand Name to Generic MedicationNCT01251419
The Impact of Social Proximity on Conversion to Generic Prescription Medications
A study testing Social Proximity and Conversion to Generic Medications in people with Conversion From Brand Name to Generic Medication, run by National Bureau of Economic Research, Inc. at 1 site in United States.
Trial summary
The goal of this project is to understand the effects of receiving peer information on individuals' conversion rates from brand name prescription medication to generic prescription medication. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Conversion From Brand Name to Generic Medication
- What is being tested?
- Social Proximity and Conversion to Generic Medications
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10,000 participants
- Where
- 1 siteUnited States
- Study dates
- Mar 2011to May 2012
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Employee of a company that uses Express Scripts as its pharmacy benefits manager.
- Employee at a company with predominantly union employees.
- Currently taking a brand name medication with an exact generic equivalent.
Who cannot join
- Employees on any psychological prescription medication.
Trial locations and contacts
1 site in 1 country.
About this study
The goal of this project is to understand the effects of receiving peer information on individuals' conversion rates from brand name prescription medication to generic prescription medication.
Read the detailed description
At companies where employees are predominantly union members, we will compare the efficacy of a peer information intervention using a testimonial from a union identified employee to an intervention using a testimonial with no union identification, as well as to a no-testimonial intervention.
The control arm will receive a letter signed by our partner company's Chief Medical Officer, explaining the health and monetary benefits of switching from brand name prescription medication to generic prescription medication. The testimonial treatment arm will receive the exact same letter, but the letter will feature an employee's testimonial along with the first name, last initial, city and state of the employee giving the testimonial. The testimonial and union arm will receive the same letter as the testimonial treatment arm but with the addition of the union affiliation of the employee giving the testimonial.
- Being tested
- Social Proximity and Conversion to Generic Medications
- Keywords
- Generic Medication, Brand Name Medication, Conversion Rates, Social Proximity, Behavioral Economics
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Social Proximity and Conversion to Generic MedicationsOther
At companies where employees are predominantly union members, we will compare the efficacy of a peer information intervention using a testimonial from a union identified employee to an intervention using a testimonial with no union identification, as well as to a no-testimonial intervention.
| Study group | Role | What they receive |
|---|---|---|
| Testimonial and Union Arm | Experimental | The testimonial and union arm will receive the same letter as the testimonial treatment arm but with the addition of the union affiliation of the employee giving the testimonial. Receives: Other: Social Proximity and Conversion to Generic Medications |
| Control | Experimental | The control arm will receive a letter signed by our partner company's Chief Medical Officer, explaining the health and monetary benefits of switching from brand name prescription medication to generic prescription medication. Receives: Other: Social Proximity and Conversion to Generic Medications |
| Testimonial Treatment Arm | Experimental | The testimonial treatment arm will receive the exact same letter as the control arm, but the letter will feature an employee's testimonial along with the first name, last initial, city and state of the employee giving the testimonial. Receives: Other: Social Proximity and Conversion to Generic Medications |
What is being measured
The primary outcome is the main question the study is designed to answer.
Conversion from Brand Name to Generic Prescription Medication
We will measure conversion rates of employees from brand name to generic prescription medication by treatment arm.
Measured: One month to one year after the intervention.
Secondary outcomes (1)
Union Status and Conversation to Generic Medication
We will see how union affiliation affects the employee conversion rates from brand name to prescription medication by treatment arm.
Measured: One month to one year after the intervention.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Dec 2010 (estimated)
- Study startMar 2011
- Primary completionMay 2012
- Study completionMay 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Conversion From Brand Name to Generic MedicationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 10,000 participants (actual)
Sponsor and investigators
- Lead sponsor
- National Bureau of Economic Research, Inc.
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute on Aging (NIA)
- Responsible party
- Sponsor
- Investigators
- David Laibson, Ph.D, Principal investigator, National Bureau of Economic Research
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01251419
- Sponsor's protocol ID
- 0002
- Other IDs
- P30AG034532
- Status last verified
- May 2012
- First submitted
- 30 Nov 2010
- Last updated
- 18 May 2012
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 May 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Impact of Social Proximity on Conversion to Generic Prescription Medications
- ClinicalTrials.gov ID
- NCT01251419
- Acronym / sponsor ID
- 0002
- Keywords
- Generic Medication, Brand Name Medication, Conversion Rates, Social Proximity, Behavioral Economics
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 10,000 participants (actual)
- Lead sponsor
- National Bureau of Economic Research, Inc.University, hospital or other
- Collaborators
- National Institute on Aging (NIA)
- Study start
- Mar 2011
- Primary completion
- May 2012 (actual)
- Study completion
- May 2012 (actual)
- First posted
- 1 Dec 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this project is to understand the effects of receiving peer information on individuals' conversion rates from brand name prescription medication to generic prescription medication.
Detailed description
At companies where employees are predominantly union members, we will compare the efficacy of a peer information intervention using a testimonial from a union identified employee to an intervention using a testimonial with no union identification, as well as to a no-testimonial intervention.
The control arm will receive a letter signed by our partner company's Chief Medical Officer, explaining the health and monetary benefits of switching from brand name prescription medication to generic prescription medication. The testimonial treatment arm will receive the exact same letter, but the letter will feature an employee's testimonial along with the first name, last initial, city and state of the employee giving the testimonial. The testimonial and union arm will receive the same letter as the testimonial treatment arm but with the addition of the union affiliation of the employee giving the testimonial.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Testimonial and Union Arm | Experimental | Other: Social Proximity and Conversion to Generic MedicationsThe testimonial and union arm will receive the same letter as the testimonial treatment arm but with the addition of the union affiliation of the employee giving the testimonial. |
| Control | Experimental | Other: Social Proximity and Conversion to Generic MedicationsThe control arm will receive a letter signed by our partner company's Chief Medical Officer, explaining the health and monetary benefits of switching from brand name prescription medication to generic prescription medication. |
| Testimonial Treatment Arm | Experimental | Other: Social Proximity and Conversion to Generic MedicationsThe testimonial treatment arm will receive the exact same letter as the control arm, but the letter will feature an employee's testimonial along with the first name, last initial, city and state of the employee giving the testimonial. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Employee of a company that uses Express Scripts as its pharmacy benefits manager.
- Employee at a company with predominantly union employees.
- Currently taking a brand name medication with an exact generic equivalent.
Key exclusion criteria (1 listed)
- Employees on any psychological prescription medication.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Social Proximity and Conversion to Generic MedicationsAt companies where employees are predominantly union members, we will compare the efficacy of a peer information intervention using a testimonial from a union identified employee to an intervention using a testimonial with no union identification, as well as to a no-testimonial intervention. | Other | Control, Testimonial Treatment Arm, Testimonial and Union Arm |
Primary outcome
Conversion from Brand Name to Generic Prescription Medication
Time frame: One month to one year after the intervention.
We will measure conversion rates of employees from brand name to generic prescription medication by treatment arm.
1 secondary outcome
Union Status and Conversation to Generic Medication
Time frame: One month to one year after the intervention.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 May 2012.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
David Laibson, Ph.D principal investigator
National Bureau of Economic Research
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Social Proximity and Conversion to Generic Medications in people with Conversion From Brand Name to Generic Medication, run by National Bureau of Economic Research, Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 May 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Conversion from Brand Name to Generic Prescription Medication (time frame: One month to one year after the intervention.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 May 2012.